In GSK’s Hoos, Scorpion gains oncology pathfinder to match its $270M war chest
Departure follows rebuild of pharma’s cancer pipeline
GSK is losing one of the principal architects of its oncology renaissance as immuno-oncology pioneer Axel Hoos prepares to leave the company for his first CEO post, at well-funded Boston cancer start-up Scorpion.
Hoos is joining Scorpion Therapeutics Inc. in August after six years as therapeutic area head for oncology at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Hoos, who added R&D governance chair to his title in 2018, has been with the company since joining as VP of immuno-oncology in 2012 after a six-year tenure at Bristol Myers Squibb Co. (NYSE:BMY). At BMS, he developed anti-CTLA-4 antibody Yervoy ipilimumab, the first FDA-approved checkpoint immunotherapy. ...